Rapamycin is included in human heart stents mainly because it prevents the growth of scar tissue due to overproliferation of vascular smooth muscle cells. Not because it prevents growth of plaque in humans. It is a potent antifibrotic. Scar tissue is what usually causes rapid restenosis of heart stents, not plaque.
Plaque and scar tissue are different things. Plaque is a complex accumulation of lipids, inflammatory cells, and fibrous tissue that develops over a long period, while arterial scar tisue (neointimal hyperplasia) is a rapid, short-term healing response to vessel injury.
Rapamycin does NOT inhibit the growth of plaque in the arteries of marmosets (the shortest lived primate). This has been rigorously tested by Adam Salmon’s research group. It unfortunately does not work:
↪ Rapamycin did not slow atherosclerosis in marmosets, and why stents use it anyway
facebook.com/share/p/1BUAKN4d4M
Marmosets are much closer to humans than mice.
#rapamycinHD #stentsHD #marmosetsHD #adamsalmonHD #mtorHD #restenosisHD #vsmcHD



